MediWound Ltd. announced it has entered into a research collaboration agreement with MIMEDX Group, Inc. MIMEDX will provide its market leading placental tissue allograft EPIFIX® to be used during the wound healing phase of the EscharEx® Phase III study in venous leg ulcers (VLUs).
EscharEx is being evaluated in a Phase III study for efficacy and safety in the debridement of chronic wounds in VLUs, the first indication being studied. In the trial, once a subject?s wound is completely debrided and the wound bed is covered with 100% granulation tissue, the patient will have either an autograft (a minor surgical procedure using the patient?s own tissue as the graft) or allograft (some form of donated tissue) applied to the wound to facilitate complete closure.